Haptenized Viral Vaccines
Viral Infections
PreclinicalResearch
Key Facts
About BioVaxys
BioVaxys is a clinical-stage biopharma company focused on harnessing the immune system to combat cancer and infectious diseases. Its strategic acquisition of IMV Inc. transformed the company, providing a validated DPX™ delivery platform and mid-stage clinical assets, most notably the Phase 2B cancer vaccine maveropepimut-S (MVP-S). The company's business model centers on advancing its platform and pipeline to proof-of-concept before out-licensing to larger partners for late-stage development and commercialization.
View full company profileTherapeutic Areas
Other Viral Infections Drugs
| Drug | Company | Phase |
|---|---|---|
| Cell-based Antiviral Drug Discovery Platform | Lucerna | Development |
| XAV19 | Xenothera | Preclinical |
| Antiviral Screening Services | NeoVirTech | Pre-clinical |
| Anti-Viral Program | MicroQuin | Pre-clinical |
| Satiasolv | Marinomed Biotech | Pre-clinical |
| Telomir-1 | Telomir Pharmaceuticals | Pre-clinical |
| DehydraTECH for Antivirals | Lexaria Bioscience | Preclinical |